PMV Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
PMVP$1.22-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
Condensed Consolidated Statements of Opera tions and Comprehensive Loss
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development | $16,063 | $18,210 | $46,069 | $54,050 |
| General and administrative | 4,000 | 4,312 | 11,894 | 12,914 |
| Total operating expenses | 20,063 | 22,522 | 57,963 | 66,964 |
| Loss from operations | (20,063) | (22,522) | (57,963) | (66,964) |
| Other income (expense): | ||||
| Interest income, net | 830 | 1,480 | 2,598 | 5,105 |
| Other expense, net | (21) | (23) | (10) | (44) |
| Change in fair value of warrant liability | (12,781) | — | (12,781) | — |
| Offering costs allocated to warrant liability | (2,344) | — | (2,344) | — |
| Total other (expense) income, net | (14,316) | 1,457 | (12,537) | 5,061 |
| Loss before benefit for income taxes | (34,379) | (21,065) | (70,500) | (61,903) |
| Benefit from income taxes | (7) | (6) | (4) | (2,198) |
| Net loss | (34,372) | (21,059) | (70,496) | (59,705) |
| Unrealized (loss) gain on available-for-sale investments, net of tax | (76) | 69 | (244) | (55) |
| Foreign currency translation gain | 2 | 1 | 4 | 7 |
| Total other comprehensive (loss) income | (74) | 70 | (240) | (48) |
| Total comprehensive loss | $(34,446) | $(20,989) | $(70,736) | $(59,753) |
| Net loss per share - basic and diluted | $(0.52) | $(0.40) | $(1.22) | $(1.14) |
| Weighted-average common shares outstanding, basic and diluted | 66,229,345 | 52,993,238 | 57,696,584 | 52,322,523 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.